In preclinical tumor models, mTOR inhibition has been shown to reduce the accumulation of MDSCs in tumors and to promote the differentiation of TAMs into M1-like, inflammatory macrophages capable of enhancing antigen presentation and stimulating T cell activation in hepatocellular carcinoma, breast cancer, lung cancer, colorectal cancer, melanoma, ovarian cancer and pancreatic cancer (93, 94). Here, MTOR is linked to neoplasm.